The oral medication tafamidis meglumine appears to be well tolerated by adults with familial amyloid polyneuropathy (FAP) in France, where the treatment is…
News
Taiwanese people with familial amyloid polyneuropathy (FAP) have a significantly altered composition of intestinal bacteria relative to their unrelated healthy family members, a new…
Getting genetic counseling can encourage people at risk for hereditary transthyretin amyloidosis to have genetic testing and know they have the option to seek early…
Rising levels of a protein called neurofilament light chain (NfL) in the blood may indicate nerve damage due to familial amyloid polyneuropathy (FAP) even…
Wainua (eplontersen) is able to slow disease progression and improve life quality for people with familial amyloid polyneuropathy (FAP) regardless of nutritional status,…
A new mutation in the TTR gene was identified as the cause of late-onset familial amyloid polyneuropathy (FAP) in an elderly man in Argentina,…
Tegsedi (inotersen) safely and effectively slowed the progression of polyneuropathy, or damage to multiple nerves, when taken for up to about six years for…
Four years of treatment with Onpattro (patisiran) safely prevents disease progression for most familial amyloid polyneuropathy (FAP) patients, according to a retrospective real-world study…
Among familial amyloid polyneuropathy (FAP) patients carrying the most common FAP-causing mutation Val30Met, treatment with tafamidis meglumine is most effective when given at the…
A noninvasive test that measures axonal excitability, or the processes that underlie electrical impulses along nerve fibers, could distinguish between the early and later stages…
Recent Posts
- Scientists ID blood markers that predict heart risk in ATTR-CM
- Navigating amyloidosis treatment can be challenging for older adults
- Tiny skin biopsies may help diagnose transthyretin amyloidosis: New study
- Early diagnosis, treatment improves survival in ATTR-CM: Study
- FDA lifts clinical hold on Phase 3 trial of nex-z for hATTR-PN